Efficiency Control of Fluticasone/Formoterol K-haler (Medium Strength) vs ICS/LABA (High Strength) in Asthma Patients
Condition: Persistent Asthma Interventions: Combination Product: fluticasone/formoterol k-haler (medium strength); Combination Product: Standard of care (ICs/LABA high strength) Sponsors: Mundipharma Pharmaceuticals S.L.; Alpha Bioresearch S.L.; Dynamic Solutions Not yet recruiting
Publication date: October 2020Source: Brain, Behavior, and Immunity, Volume 89Author(s): Xiaoqin Liu, Trine Munk-Olsen, Clara Albiñana, Bjarni J. Vilhjálmsson, Emil M. Pedersen, Vivi Schlünssen, Marie Bækvad-Hansen, Jonas Bybjerg-Grauholm, Merete Nordentoft, Anders D. Børglum, Thomas Werge, David M. Hougaard, Preben B. Mortensen, Esben Agerbo
Publication date: Available online 9 October 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Manuel Jorge Rial, Marcela Valverde, Victoria del Pozo, Francisco Javier González-Barcala, Carlos Martínez-Rivera, Xavier Muñoz, José María Olaguibel, Vicente Plaza, Elena Curto, Santiago Quirce, Pilar Barranco, Javier Domínguez-Ortega, Joaquin Mullol, César Picado, Antonio Valero, Irina Bobolea, Ebymar Arismendi, Paula Ribó, Joaquín Sastre
Purpose of Study: Explore the perceptions of primary care physicians (PCPs) from community health care centers (CHCs) in Franklin County, Ohio, regarding factors that contribute to their inability to consistently provide sustainable asthma management services to their uninsured patient population. Primary Practice Setting: Asthmatic patients are not consistently receiving sustainable asthma management in CHCs in Ohio. Primary care physicians in CHCs play a pivotal role in closing health care gaps for asthmatic patients. To minimize the barriers that impede the efforts of PCPs to control asthma for their uninsured pati...
Publication date: Available online 9 October 2020Source: Pulmonary Pharmacology &TherapeuticsAuthor(s): Osamu Matsuno, Seijiro Minamoto
Publication date: Available online 8 October 2020Source: Pulmonary Pharmacology &TherapeuticsAuthor(s): Francesco Menzella, Patrizia Ruggiero, Carla Galeone, Chiara Scelfo, Diego Bagnasco, Nicola Facciolongo
Publication date: Available online 8 October 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Annelies L. Robijn, Daniel Barker, Peter G. Gibson, Warwick B. Giles, Vicki L. Clifton, Joerg Mattes, Michael J. Peek, Helen L. Barrett, Sean K. Seeho, Leonie K. Callaway, Alistair Abbott, John Attia, Peter A. Wark, Megan E. Jensen, Vanessa E. Murphy
Publication date: Available online 8 October 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Yudy K. Persaud., Jay Portnoy
Publication date: Available online 8 October 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Laurits Frøssing, Alexander Silberbrandt, Anna Von Bülow, Vibeke Backer, Celeste Porsbjerg
tivitis Committee Abstract Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used throughout the world. They are frequently involved in hypersensitivity reactions, which range from local or mild reactions to systemic and severe reactions. Consequently, it is necessary to perform an exhaustive study of patients in order to make an accurate diagnosis, search for safe procedures in the case of severe reactions, and identify alternative treatment options. Various guidelines and protocols address the management of hypersensitivity to NSAIDs, although these vary widely from country to country. The Committees of A...
CONCLUSION: Treatment of SAA with omalizumab improves the outcome of associated CRSNP+, thus supporting the concept of a "one airway disease". PMID: 30931917 [PubMed - indexed for MEDLINE]